Menopause Symptoms: When to See a Doctor

What Causes Menopause Symptoms?

Menopause symptoms arise from declining ovarian estrogen and progesterone production. The hypothalamus, which regulates body temperature and multiple physiological set points, is highly sensitive to estrogen withdrawal. As estrogen falls, the thermoregulatory neutral zone narrows, triggering vasomotor instability that produces hot flashes and night sweats. Secondary effects ripple through cardiovascular, skeletal, urogenital, and neurological systems. The process is gradual; perimenopause, the transitional phase before the final menstrual period, can last 4 to 10 years.

Hormonal Drivers

Estradiol levels drop by roughly 85 to 90% in the years surrounding the final menstrual period. Follicle-stimulating hormone (FSH) rises simultaneously as the pituitary attempts to stimulate exhausted ovarian follicles. This FSH surge, often above 30 IU/L, is the lab finding used to confirm menopause when clinical history is ambiguous. Progesterone also declines, contributing to irregular bleeding and sleep disruption during perimenopause.

Non-Ovarian Contributing Factors

Genetics account for roughly 50% of the variance in symptom severity, based on twin studies. Body mass index matters: adipose tissue aromatizes androgens to estrone, so women with higher BMI sometimes have milder vasomotor symptoms but face greater risks of insulin resistance and endometrial hyperplasia. Smoking accelerates follicular depletion and brings menopause an average 1 to 2 years earlier. Surgical menopause, caused by bilateral oophorectomy, produces an abrupt estrogen fall and typically generates more severe symptoms than natural menopause.

The Brain-Temperature Connection

The hypothalamic neurons expressing kisspeptin, neurokinin B, and dynorphin (KNDy neurons) are directly modulated by estrogen. When estrogen drops, KNDy neuron activity increases, lowering the thermoregulatory set point and narrowing the thermal comfort zone to near zero. Fezolinetant (Veozah), a neurokinin-3 receptor antagonist approved by the FDA in May 2023, targets exactly this pathway and reduces moderate-to-severe hot flash frequency without hormones.

How Is Menopause Diagnosed?

Menopause is diagnosed clinically after 12 consecutive months of amenorrhea in a woman over 40 with no other medical cause. Lab testing is often unnecessary but helps in ambiguous cases. The 2023 Menopause Society Position Statement states: "Menopause is a clinical diagnosis; FSH and estradiol testing should be reserved for women under 45 or those on hormonal contraception that masks bleeding patterns."

Clinical Criteria

A complete menstrual history is the starting point. Clinicians look for the characteristic progression: cycle irregularity (shortened or lengthened intervals), skipped periods, and then cessation. Vasomotor symptoms, sleep disruption, and mood changes often intensify during this transition. Most women aged 45 to 55 presenting with these features do not need lab confirmation.

Laboratory Testing

When a diagnosis is uncertain, a single-morning FSH level above 30 IU/L combined with estradiol below 20 pg/mL on two measurements taken at least 4 to 6 weeks apart is consistent with menopause. Thyroid-stimulating hormone (TSH) should be checked at the same visit because hypothyroidism overlaps significantly with menopause symptoms, including fatigue, weight gain, and mood changes. Anti-Müllerian hormone (AMH) testing, while useful for assessing ovarian reserve in fertility contexts, is not part of routine menopause diagnosis.

Premature Ovarian Insufficiency

Women who develop menopause symptoms before age 40 require a different workup. Premature ovarian insufficiency (POI) affects roughly 1% of women and carries a higher risk of cardiovascular disease and osteoporosis than natural menopause. Chromosome analysis and autoimmune screening are recommended, and hormone therapy in this population is generally continued until the average age of natural menopause (approximately 51 years).

Which Menopause Symptoms Are Normal?

The list of expected menopause symptoms is long. Recognizing them as part of the menopausal transition prevents unnecessary alarm, but it does not mean treatment is unavoidable. Effective options exist for virtually every symptom on the list below.

Vasomotor Symptoms (Hot Flashes and Night Sweats)

Hot flashes affect up to 80% of women and are the most common reason for seeking clinical care. The Study of Women's Health Across the Nation (SWAN) followed 1,449 women and found that vasomotor symptoms persisted for a median of 7.4 years, with the longest duration in women who began having symptoms in perimenopause rather than after the final period. Each episode typically lasts 1 to 5 minutes, begins in the chest or face, and radiates outward with sweating and a rapid heart rate.

Night sweats are hot flashes occurring during sleep. They fragment sleep architecture, reduce slow-wave sleep, and contribute to next-day fatigue and cognitive complaints. Treating the night sweats often resolves the associated brain-fog symptoms without any additional intervention.

Genitourinary Syndrome of Menopause (GSM)

GSM is the current clinical term for vaginal dryness, atrophy, dyspareunia, and urinary urgency caused by estrogen withdrawal from urogenital tissue. The International Society for the Study of Women's Sexual Health estimates GSM affects 27 to 84% of postmenopausal women, yet fewer than 25% discuss it with a clinician. Unlike vasomotor symptoms, GSM rarely resolves without treatment and typically worsens over time.

Sleep, Mood, and Cognition

Insomnia affects 40 to 60% of perimenopausal women, compared with 31% of premenopausal women in cross-sectional data. Mood changes, including irritability, anxiety, and depressed affect, are reported by roughly 40% of women during perimenopause. These are distinct from major depressive disorder, though perimenopause does increase the risk of a first depressive episode by approximately 2.5-fold. Cognitive complaints, particularly word retrieval difficulty and short-term memory lapses, are common but generally transient in the early postmenopausal years.

Musculoskeletal and Metabolic Changes

Joint aches affect roughly 50% of perimenopausal women and are directly linked to estrogen deficiency, separate from aging effects. Bone mineral density begins declining 1 to 2 years before the final menstrual period and accelerates to a loss of 2 to 3% per year in trabecular bone during the first 2 to 3 postmenopausal years. DEXA scanning is recommended for all women age 65 or older, and for younger postmenopausal women with clinical risk factors.

When Should You Worry About Menopause Symptoms?

Several symptoms that can appear during the menopausal transition are not caused by menopause at all and may signal a serious underlying condition. Prompt evaluation is warranted for all of the following.

Postmenopausal Bleeding

Any vaginal bleeding occurring more than 12 months after the final menstrual period is postmenopausal bleeding (PMB) until proven otherwise. PMB is the cardinal symptom of endometrial cancer, though benign causes such as atrophic endometrium and endometrial polyps account for the majority of cases. Endometrial cancer affects approximately 3% of women with PMB, making it an absolute indication for pelvic ultrasound (endometrial stripe measurement) and, if the stripe exceeds 4 mm, endometrial biopsy.

Do not attribute PMB to menopause. Schedule an appointment within 1 to 2 weeks of noticing it.

Chest Pain and Palpitations

Mild palpitations during a hot flash are common, caused by the same autonomic surge that drives the flash. Chest pain, pressure, shortness of breath, or palpitations that persist beyond a hot flash episode, occur at rest, or are accompanied by dizziness require emergency evaluation. Women's cardiovascular risk rises sharply after menopause. The American Heart Association notes that the rate of myocardial infarction in women increases significantly in the decade following natural menopause.

Severe or Rapidly Worsening Mood Changes

Mood fluctuations during perimenopause are expected. A score of 10 or higher on the PHQ-9 depression screen, suicidal ideation, panic attacks severe enough to cause functional impairment, or psychotic features are not attributable to menopause alone and require same-day or next-day psychiatric assessment.

New or Worsening Urinary Symptoms

Mild urinary urgency and stress incontinence are common in the menopausal transition due to urogenital atrophy. Dysuria, hematuria, urinary frequency with fever or flank pain, or new urinary incontinence in a woman who has not previously had it should prompt evaluation for urinary tract infection, overactive bladder, or, less commonly, bladder or renal pathology.

Unexplained Weight Loss or Fatigue

Metabolic changes during menopause can cause gradual weight redistribution. Rapid, unintentional weight loss of more than 5% of body weight over 6 to 12 months alongside fatigue, night sweats, and systemic symptoms is not a menopause presentation. It requires workup for malignancy, thyroid disease, adrenal insufficiency, or gastrointestinal pathology.

Treatments for Menopause Symptoms

Effective, evidence-based treatments exist across multiple categories. Selection depends on symptom type, severity, medical history, and patient preference.

Menopausal Hormone Therapy (MHT)

MHT, previously called HRT, is the most effective treatment for vasomotor symptoms and GSM. The 2023 Menopause Society Position Statement states: "For healthy women under age 60 or within 10 years of menopause onset, the benefits of MHT outweigh the risks for treatment of vasomotor symptoms and prevention of bone loss."

Estrogen-only MHT is used in women who have had a hysterectomy. Combined estrogen-progestogen MHT is required in women with a uterus to prevent endometrial hyperplasia. Transdermal estradiol, delivered via patch, gel, or spray, avoids first-pass hepatic metabolism and is associated with a lower risk of venous thromboembolism compared to oral formulations. Starting doses for vasomotor symptom control typically range from 0.025 mg to 0.1 mg estradiol per day transdermally, or 0.5 mg to 2 mg orally.

Non-Hormonal Prescription Options

For women who cannot or prefer not to use MHT, several non-hormonal options carry FDA approval or strong evidence:

• Fezolinetant (Veozah) 45 mg daily. FDA-approved May 2023 for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 4 trial (N=1,830), fezolinetant reduced hot flash frequency by 56.4% vs. 39.9% placebo at 52 weeks.
• Paroxetine 7.5 mg (Brisdelle). The only FDA-approved SSRI for vasomotor symptoms. Effect size is modest: approximately 1.8 fewer hot flashes per day vs. Placebo in Phase III trials.
• Venlafaxine 75 mg daily and escitalopram 10 to 20 mg daily show comparable efficacy to paroxetine in randomized trials and are commonly used off-label.
• Gabapentin 300 mg at bedtime reduces nocturnal hot flashes and may improve sleep quality, though evidence is weaker than for SSRIs or SNRIs.

Local Estrogen for GSM

Low-dose vaginal estrogen, available as a cream (Estrace, Premarin), vaginal ring (Estring), tablet (Vagifem), or suppository (Imvexxy), delivers estrogen directly to urogenital tissue with minimal systemic absorption. A 2022 Cochrane review of 30 randomized controlled trials found that local estrogen significantly reduced vaginal dryness, dyspareunia, and urinary urgency compared to placebo, with no statistically significant effect on systemic estrogen levels at labeled doses.

Ospemifene (Osphena) 60 mg daily is an oral selective estrogen receptor modulator FDA-approved for dyspareunia due to GSM, offering an alternative for women who decline vaginal administration.

Lifestyle Modifications With Evidence

Lifestyle changes alone rarely eliminate moderate-to-severe vasomotor symptoms, but they reduce frequency and severity meaningfully.

• Cognitive behavioral therapy (CBT). A randomized trial in Menopause (Hunter et al., 2019, N=128) found that 6 sessions of CBT reduced hot flash problem rating by 49% vs. 22% in the control group at 6 months.
• Clinical hypnosis reduced hot flash scores by 74% vs. 17% in a randomized trial at Baylor University (Elkins et al., N=187).
• Weight loss of 10 lbs or more was associated with a 33% increase in the likelihood of hot flash resolution at 2 years in the MsFLASH trial (N=338).

Bone Protection

Women with postmenopausal osteoporosis or osteopenia and additional fracture risk factors may require treatment beyond calcium and vitamin D. Bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) are first-line per National Osteoporosis Foundation guidelines. MHT also prevents bone loss and reduces fracture risk, making it an efficient option for women who need both symptom control and skeletal protection.

The HealthRX Clinical Decision Framework for Menopause Symptoms

The following triage framework is used by HealthRX clinicians during initial menopause consultations. It is not a substitute for individualized evaluation.

Tier 1 (Same-day or ER): Chest pain with dyspnea, suicidal ideation, hematuria with systemic symptoms, postmenopausal bleeding with hemodynamic instability.

Tier 2 (Within 1 to 2 weeks): Postmenopausal bleeding (any amount), new urinary symptoms not explained by recent infection, PHQ-9 score 10 or above, unintentional weight loss greater than 5% over 6 months.

Tier 3 (Routine appointment, within 4 to 6 weeks): Moderate-to-severe hot flashes affecting sleep or work, GSM symptoms causing dyspareunia or urinary urgency, joint pain without prior diagnosis, request to start or adjust MHT.

Tier 4 (Annual wellness visit): Mild vasomotor symptoms not affecting daily function, early sleep changes, mild cognitive complaints without functional impact, discussion of bone health and cardiovascular risk.

What to Expect at Your Appointment

Preparing for a menopause-focused visit improves the quality of care you receive. Bring a 2-week diary tracking hot flash frequency and severity, a list of all current medications (including supplements), your most recent Pap smear and mammogram dates, and your personal and family history of breast, endometrial, and ovarian cancer.

Your clinician will likely complete a physical exam including blood pressure, BMI, and a pelvic exam to assess for urogenital atrophy. Labs ordered at a first visit commonly include TSH, FSH, estradiol, fasting lipids, fasting glucose, and a complete blood count. Bone density screening via DEXA is ordered if you are 65 or older, or younger with risk factors such as low body weight, prior fragility fracture, or long-term glucocorticoid use.

Expect an honest conversation about MHT candidacy. Women with a history of estrogen-receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, or a personal history of venous thromboembolism or stroke may not be candidates for systemic MHT. For most healthy women under 60 within 10 years of menopause onset, the absolute risks of MHT are small and the quality-of-life benefits are substantial.